Patient Preferences for Non-Small-Cell Lung Cancer Treatment Options

  • Date:
  • Location: Online
  • Lecturer: Isabelle Huys, Rosanne Janssens, Meredith Smith, Serena Oliveri
  • Contact person: Carl Steinbeisser
  • Seminarium

One of PREFER’s core case studies explored patient preferences for lung cancer treatments, assessing which trade-offs between benefit and risks related to treatment alternatives that patients are willing to accept or not. In this webinar, we describe the design of the study, its main results and lesson learnt in conducting the preference study with this vulnerable population of patients.

In the treatment paradigm for Non-Small Cell Lung Cancer (NSCLC) the combination of Immuno-Oncotherapy (IO) and chemotherapy (CT) (approved by the FDA and EMA) was found to be superior to CT alone in terms of both progression-free survival (PFS) and overall survival OS. While the clinical benefit of combined chemo-immunotherapy is clear for patients with PD-L1 low/negative NSCLC for which the only alternative is standard chemotherapy, data are less clear for those with PD-L1 positive NSCLC who can choose between IO and chemo-immunotherapy combination. Patients and clinicians have to face a choice between a more aggressive treatment with a greater impact on the quality of life versus an alternative that may be less effective but that carries fewer side effects.

In this webinar, we will provide a brief explanation of the disease and the decision making sensitive situation, how the patient preference study was designed and its main results. We will then discuss what implications the results may have and the lessons learned in conducting the study.

Register to participate